{
    "clinical_study": {
        "@rank": "84226", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent\n      or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use\n      different ways to stop cancer cells from dividing so they stop growing or die"
        }, 
        "brief_title": "506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma", 
        "condition": [
            "Angioimmunoblastic T-cell Lymphoma", 
            "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", 
            "Nodal Marginal Zone B-cell Lymphoma", 
            "Recurrent Adult T-cell Leukemia/Lymphoma", 
            "Recurrent Grade 1 Follicular Lymphoma", 
            "Recurrent Grade 2 Follicular Lymphoma", 
            "Recurrent Marginal Zone Lymphoma", 
            "Recurrent Small Lymphocytic Lymphoma", 
            "Splenic Marginal Zone Lymphoma", 
            "Waldenstr\u00f6m Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Immunoblastic Lymphadenopathy", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, T-Cell", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Waldenstrom Macroglobulinemia", 
                "Lymphoma, B-Cell", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral", 
                "Lymphoma, B-Cell, Marginal Zone"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response rate, failure-free survival, and progression-free survival of\n      patients with recurrent or refractory indolent B-cell non-Hodgkin's lymphoma or peripheral\n      T-cell lymphoma when treated with 506U78.\n\n      II. Assess the pharmacokinetics and toxicity of this treatment in these patients.\n\n      OUTLINE:\n\n      Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days\n      for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma or\n             peripheral T-cell lymphoma\n\n               -  Indolent B-cell lymphoma will include Waldenstr\u00f6m's macroglobulinemia,\n                  lymphoplasmacytoid lymphoma small lymphocytic lymphoma, marginal zone lymphoma,\n                  and follicular small cleaved-cell or mixed cell lymphoma; patients with prior or\n                  concurrent evidence of transformation to large cell lymphoma or with follicular\n                  large cell lymphoma are ineligible\n\n               -  Peripheral T-cell lymphoma will include all entities described in the REAL\n                  classification; patients with B-cell ALCL are ineligible; patients with\n                  cutaneous T-cell lymphoma and all its variants and/or histologic transformation\n                  of cutaneous T-cell lymphoma are not eligible for this protocol, because they\n                  will be instead eligible for a separate protocol\n\n               -  Relapsed peripheral T-cell lymphomas include all those achieving and maintaining\n                  a complete or partial response during initial therapy; refractory includes those\n                  achieving all other responses during initial therapy; since the response rate of\n                  indolent B-cell lymphomas to up-front therapy exceeds 90% this distinction is\n                  not meaningful there\n\n          -  No more than 2 prior chemotherapy and one prior immunotherapy regimens; if\n             chemoimmunotherapy was used, the limit will be 3 prior regimens\n\n          -  Performance status =< 2 Zubrod\n\n          -  Staging work-up within 3 weeks and bidimensionally measurable disease\n\n          -  No anti-cancer treatment within the past three weeks\n\n          -  ANC >= 1,000/ul; may be included if in the judgment of the study chairman lower\n             counts are explained by marrow or splenic involvement by lymphoma\n\n          -  Platelets >= 100,000/ul; may be included if in the judgment of the study chairman\n             lower counts are explained by marrow or splenic involvement by lymphoma\n\n          -  Bilirubin =< 1.5 x normal\n\n          -  SGPT =< 2.5 x normal values\n\n          -  Estimated endogenous creatinine clearance > 50 ml/min\n\n          -  HIV negative; the patients are excluded because the expected opportunistic infections\n             will render study toxicity difficult to interpret; in addition the possible effects\n             of 506U78 on CD4 cells may be dangerous to these patients; furthermore, indolent\n             B-cell lymphomas and aggressive peripheral T-cell lymphomas are extremely rare in the\n             setting of HIV infection\n\n          -  No active CNS disease\n\n          -  No other malignancy within the last 5 years, except basal cell carcinoma of the skin\n             or in-situ cervical carcinoma treated with curative intent\n\n          -  Females must not be pregnant or breast feeding and must be practicing adequate\n             contraception; this is because 506U78 may be harmful to the developing fetus and\n             nursing newborn or infant\n\n          -  No preexisting sensory or motor neuropathy of grade \u2265 2, no history of seizures\n\n          -  No prior stem cell or bone marrow transplantation; no prior 506U78\n\n          -  All patients, including women or members of a minority that fulfill criteria for\n             study entry will be eligible for treatment; no one fulfilling all these criteria for\n             entry will be denied treatment solely on the basis of sex or minority status\n\n          -  Patients with medical, psychiatric, or social conditions that make compliance with\n             treatment or follow-up unlikely are not eligible\n\n          -  No history of symptomatic cardiac dysfunction or pericardial effusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "111", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005950", 
            "org_study_id": "NCI-2012-02339", 
            "secondary_id": [
                "ID99-208", 
                "N01CM17003", 
                "CDR0000067894"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Given IV", 
            "intervention_name": "nelarabine", 
            "intervention_type": "Drug", 
            "other_name": [
                "506U78", 
                "Arranon", 
                "GW506U78"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M D Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of 506U78 (NSC #686673) for Patients With Relapsed or Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Andre Goy", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response rate (RR), defined as CR + PR", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Failure-free survival", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013", 
        "why_stopped": "Administratively complete."
    }, 
    "geocoordinates": {
        "M D Anderson Cancer Center": "29.76 -95.369"
    }
}